Dashboard
Manage Tickers

LEXXWLexaria Bioscience Corp.

Nasdaq www.lexariabioscience.com


$ 1.04 $ -0.05 (-5 %)    

Friday, 13-Sep-2024 14:25:32 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 472.49 $ -2.05 (-0.43 %)
DIA $ 416.26 $ -1.07 (-0.26 %)
SPY $ 562.20 $ -1.67 (-0.3 %)
TLT $ 99.62 $ -1.25 (-1.24 %)
GLD $ 235.53 $ -1.83 (-0.77 %)
$ 0.9499
-- x --
-- x --
-- - --
$ 0.05 - $ 2.50
261,343
na
50.91M
$ 1.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-12-2024 05-31-2024 10-Q
2 04-09-2024 02-29-2024 10-Q
3 01-12-2024 11-30-2023 10-Q
4 11-20-2023 08-31-2023 10-K
5 07-14-2023 05-31-2023 10-Q
6 04-14-2023 02-28-2023 10-Q
7 01-17-2023 11-30-2022 10-Q
8 11-28-2022 08-31-2022 10-K
9 07-14-2022 05-31-2022 10-Q
10 04-11-2022 02-28-2022 10-Q
11 01-14-2022 11-30-2021 10-Q
12 11-27-2021 08-31-2021 10-K
13 07-15-2021 05-31-2021 10-Q
14 04-14-2021 02-28-2021 10-Q
15 01-14-2021 11-30-2020 10-Q
16 10-15-2020 08-31-2020 10-K
17 06-30-2020 05-31-2020 10-Q
18 04-03-2020 02-29-2020 10-Q
19 01-09-2020 11-30-2019 10-Q
20 11-14-2019 08-31-2019 10-K
21 07-08-2019 05-31-2019 10-Q
22 04-15-2019 02-28-2019 10-Q
23 01-11-2019 11-30-2018 10-Q
24 11-14-2018 08-31-2018 10-K
25 07-13-2018 05-31-2018 10-Q
26 04-12-2018 02-28-2018 10-Q
27 01-12-2018 11-30-2017 10-Q
28 11-27-2017 08-31-2017 10-K
29 07-14-2017 05-31-2017 10-Q
30 04-14-2017 02-28-2017 10-Q
31 01-13-2017 11-30-2016 10-Q
32 11-29-2016 08-31-2016 10-K
33 07-13-2016 05-31-2016 10-Q
34 04-13-2016 02-29-2016 10-Q
35 01-08-2016 11-30-2015 10-Q
36 11-27-2015 08-31-2015 10-K
37 07-14-2015 05-31-2015 10-Q
38 04-14-2015 02-28-2015 10-Q
39 01-14-2015 11-30-2014 10-Q
40 09-11-2014 07-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Lexaria Bioscience Announces Tolerability ...
08/29/2024 13:36:37

Absorption improvements appear to continue with DehydraTECH-processed Rybelsus® vs. Rybelsus® tablets even under "fed" ...

Core News & Articles
Lexaria Preparing For Strategic Growth, Ex...
07/16/2024 13:30:09

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...

Core News & Articles
Lexaria Receives 3 New Patents For Antivir...
07/08/2024 13:20:09

Lexaria currently holding 46 granted patents worldwideKELOWNA, BC / ACCESSWIRE / July 8, 2024 / Lexaria Bioscience Corp. (NASDA...

Core News & Articles
Lexaria Awards Contract To A CRO To Perfor...
05/23/2024 14:56:55

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral formatKELOWNA, BC / ACCESSWIRE / M...

Core News & Articles
Lexaria Announces New Research Program To ...
05/06/2024 13:08:30

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...

Core News & Articles
Lexaria To Receive $4.7M Gross Proceeds In...
04/30/2024 19:53:35

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...

Core News & Articles
Lexaria Receives Ethics Review Board Appro...
04/16/2024 13:17:08

Human Pilot Study #2 (GLP-1-H24-2) ApprovedKELOWNA, BC / ACCESSWIRE / April 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(N...

Core News & Articles
Lexaria Appoints Nelson Cabatuan As Chief ...
03/14/2024 13:22:01

Lexaria Bioscience Corp.

Core News & Articles
Lexaria To Begin Diabetes And Weight Loss ...
03/05/2024 14:10:01

Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be testedChronic dosing over a 12-week treatment periodWill asse...

Core News & Articles
Lexaria Bioscience Corp. Announces That Th...
12/07/2023 14:22:44

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...

Core News & Articles
Lexaria Enters New Global Exclusive Collab...
10/13/2023 13:07:41

Global exclusivity for all non-pharmaceutical applications of DehydraTECH-sulforaphane has been awarded Minimum ongoing paym...

Core News & Articles
Lexaria To Evaluate Impact Of DehydraTECH ...
09/21/2023 13:16:03

DehydraTECH-powered GLP-1 drugs will be evaluated for potential improvements such as:Reduced side effects;Enhanced weight loss;...

Core News & Articles
Lexaria Provides Update On Investigational...
08/30/2023 13:24:31

 Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug ...

Core News & Articles
Lexaria's Plans To Study Weight Loss And D...
08/02/2023 13:14:12

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...

Core News & Articles
Lexaria Incorporates New Subsidiary For CP...
07/28/2023 13:11:42

 Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug ...

Core News & Articles
Lexaria Granted Strategically Important Ne...
07/19/2023 13:06:40

More countries are banning e-cigarettes as novel oral products gain traction KELOWNA, BC / ACCESSWIRE / July 19, 2023 / Lex...

Core News & Articles
Lexaria's DehydraTECH-CBD Lowers Blood Glu...
06/16/2023 13:11:10

Blood glucose levels reduced by 19.9% with DehydraTECH-CBDImprovements in kidney function also demonstratedKELOWNA, BC / ACCESS...

lexarias-formulated-cannabidiol-showed-reduction-in-pro-inflammatory-biomarkers-associated-with-heart-diseases
Lexaria's Formulated Cannabidiol Showed Re...
05/23/2023 18:41:24

Core News & Articles
Lexaria's Hormone Study Shows Significant ...
05/18/2023 13:08:35

900% and 2,000% improvements in peak bloodstream delivery using DehydraTECH KELOWNA, BC / ACCESSWIRE / May 18, 2023 / Lexaria ...

Core News & Articles
Lexaria Awards CRO Contract For Upcoming U...
04/24/2023 13:05:08

Clinical study will evaluate safety and tolerability of Lexaria's patented DehydraTECH-CBD as a potential treatment for hyp...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION